Skip to main content
. 2016 May 4;14:114. doi: 10.1186/s12967-016-0869-x

Fig. 4.

Fig. 4

High initial Peroxiredoxin 1 level in cardiogenic shock patients who received ECMO support was associated with a poorer survival. Kaplan–Meier survival analysis of 7- and 30-day overall survivals in cardiogenic shock patients categorized by the cut-off values, as presented in Table 2, of their plasma Prdx1 levels at 0 (a) and 24 h (b) after receiving ECMO support